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Abstract
Background: Venous thromboembolic events (VTE), including deep venous thrombosis and pulmonary embolism,
are common in older age. It has been suggested that statins might reduce the risk of VTE however positive results
from studies of middle aged subjects may not be generalisable to elderly people. We aimed to determine the
effect of pravastatin on incident VTE in older people; we also studied the impact of clinical and plasma risk
variables.
Methods: This study was an analysis of incident VTE using data from the Prospective Study of Pravastatin in the
Elderly at Risk (PROSPER), a randomized, double-blind, placebo-controlled trial of pravastatin in men and women
aged 70-82. Mean follow-up was 3.2 years. Risk for VTE was examined in non-warfarin treated pravastatin (n =
2834) and placebo (n = 2865) patients using a Cox’s proportional hazard model, and the impact of other risk
factors assessed in a multivariate forward stepwise regression analysis. Baseline clinical characteristics, blood
biochemistry and hematology variables, plasma levels of lipids and lipoproteins, and plasma markers of
inflammation and adiposity were compared. Plasma markers of thrombosis and hemostasis were assessed in a
nested case (n = 48) control (n = 93) study where the cohort was those participants, not on warfarin, for whom
data were available.
Results: There were 28 definite cases (1.0%) of incident VTE in the pravastatin group recipients and 20 cases
(0.70%) in placebo recipients. Pravastatin did not reduce VTE in PROSPER compared to placebo [unadjusted hazard
ratio (95% confidence interval) 1.42 (0.80, 2.52) p = 0.23]. Higher body mass index (BMI) [1.09 (1.02, 1.15) p =
0.0075], country [Scotland vs Netherlands 4.26 (1.00, 18.21) p = 0.050 and Ireland vs Netherlands 6.16 (1.46, 26.00)
p = 0.013], lower systolic blood pressure [1.35 (1.03, 1.75) p = 0.027] and lower baseline Mini Mental State
Examination (MMSE) score [1.19 (1.01, 1.41) p = 0.034] were associated with an increased risk of VTE, however only
BMI, country and systolic blood pressure remained significant on multivariate analysis. In a nested case control
study of definite VTE, plasma Factor VIII levels were associated with VTE [1.52 (1.01, 2.28), p = 0.044]. However no
other measure of thrombosis and haemostasis was associated with increased risk of VTE.
Conclusions: Pravastatin does not prevent VTE in elderly people at risk of vascular disease. Blood markers of
haemostasis and inflammation are not strongly predictive of VTE in older age however BMI, country and lower
systolic blood pressure are independently associated with VTE risk.
Trial Registration: Not applicable when study undertaken.
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Background
Venous thromboembolism (VTE) has an incidence of
1-2 per 1000 individuals per year but is close to 1% per
annum in those aged over 70 years [1]. VTE is a leading
cause of death in hospital inpatients [2] and is a major
cause of morbidity and mortality particularly in older
people and among those with cancer [1,3]. Despite the
fact that 70% of patients with VTE are aged over 60 [1],
there are few studies of risk factors in the elderly. Other
studies have analyzed effects of pre-existing statin medi-
cation on incident VTE [4-6] or have compared statin
use in case control studies of VTE [7-9]. A post hoc ana-
lysis of the Heart and Estrogen/progestin Replacement
Study (HERS) [4] and analyses of other [5-8], but not all
[9], population or case control studies indicated a
decreased risk of VTE with statin use. A systematic
review of observational studies suggested that statins
may be useful in the prevention of VTE [10]. However,
observational studies are prone to confounding hence
randomized controlled trials are required to assess reli-
ably the effects of statins on VTE risk.
Recently a randomized control trial of rosuvastatin in
the prevention of VTE, in middle-aged subjects with low
LDL cholesterol and raised C-reactive protein levels,
(JUPITER) [11] indicated that rosuvastatin significantly
reduced the occurrence of symptomatic VTE, (hazard
ratio 0.57, 95% confidence interval 0.37 - 0.86, p =
0.007). Reviews of this trial and of recent case control
studies [12,13] have renewed the debate on the efficacy
of statins in the prevention of VTE and the call for ana-
lysis of prospective data. A meta-analysis suggested that
statin treatment was likely to reduce the risk of VTE,
however there was significant heterogeneity of study
outcome [14], and as the majority of studies looked at
middle-aged rather than elderly populations and there
was no separate analysis by age, it was not certain that
elderly people benefit.
The Prospective Study of Pravastatin in the Elderly at
Risk (PROSPER) was a multi-centre, randomized, dou-
ble-blind, placebo-controlled trial of pravastatin in the
prevention of vascular disease in the elderly [15]. The
present study is an analysis of incident VTE in this
population of men and women aged 70-82 using data
from the PROSPER database. The aim was to determine
whether pravastatin reduces VTE incidence in older
people. In addition, we assessed the impact of clinical,
hematological, lipid, inflammatory and vascular risk fac-
tors for incident VTE in older age.
Methods
Subjects
The design and outcome of PROSPER is described
elsewhere [15-17]. Men and women aged 70-82 (n =
5804) with evidence of pre-existing vascular disease or
at least one major risk factor for vascular disease were
randomized to placebo or pravastatin (40 mg per day)
treatment. Follow up was 3.2 years on average. For the
present study the full medical records were retrieved
for all suspected VTE in the PROSPER database and
examined by three clinicians in a pre-planned post hoc
analysis. Events were categorized as definite VTE if
death from VTE was confirmed on the death certificate
or if there was recorded evidence from investigations
such as ultrasound venography ventilation perfusion
lung scans or computed tomography pulmonary angio-
graphy. Events were categorized as probable VTE
when there was a record of at least 3 months’ continu-
ous anticoagulant treatment with warfarin or heparin
or a clinician diagnosis of VTE in the trial records plus
documentation of venous insufficiency or venous leg
ulceration but no confirmation by clinical test or
anticoagulant treatment. A consensus of two clinical
opinions was required to confirm the event categoriza-
tion. Where data were available for the entire cohort
(Figure 1, Table 1), the utility of a parameter in
predicting risk of VTE was assessed using all cases
(n = 48 definite VTE, n = 72 combined definite and
probable VTE) and non-cases (n = 5627) not on war-
farin treatment. For hemostatic variables and IGF-1
(Table 2) a nested case control study was performed.
We matched each probable and definite case (n = 76)
with 2 controls (n = 152) selected at random from all
non-cases on the basis of age (using two-year age
categories), smoking status and country of origin
(Figure 1). We excluded those controls that matched
with a probable case, leaving 96 matching 48 definite
cases, 3 of these 96 controls were on warfarin
and removed from the analysis leaving 93 controls
(Figure 1). In order to assess the impact of cancer as a
precipitating factor for VTE, cases were separated into
those who did and those who did not develop cancer
during the study (diagnosis confirmed by endpoint
committee). The institutional ethics review boards of
all centres approved the protocol [the Argyll and Clyde
Local Research Ethics Committee, the Glasgow Royal
Infirmary Local Research Ethics Committee, Greater
Glasgow Primary Care and Mental Health Research
Ethics Committee, Lanarkshire Health Board Local
Research Ethics Committee, Dumfries and Galloway
Health Board Local Research Ethics Committee, Forth
Valley Health Board Local Research Ethics Committee,
METC board of Leiden University Medical Center and
the Clinical Research Ethics Committee of The Cork
Teaching Hospitals], and all participants gave written
informed consent. The protocol was consistent with
the Declaration of Helsinki.
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Baseline data
Baseline demographics, clinical history, activities of daily
living (20-point Barthel index), instrumental activities of
daily living (14-point IADL scale) and Mini Mental State
Examination (MMSE) were collected as described
previously [16].
Baseline blood analyses
Baseline blood glucose, serum creatinine, urea, alanine
aminotransferase (ALT), aspartate aminotransferase
(AST), creatine kinase, free T4, thyroid stimulating hor-
mone, hemoglobin, hematocrit, white blood cell count
and platelet count were carried out by routine methods
[17]. Baseline plasma lipids and lipoproteins were
analyzed as described previously [18]. Baseline apolipo-
proteins AI and B were assayed by turbidimetric assays
(Hitachi/Roche) as described previously [18]. Plasmino-
gen Activator Inhibitor-1, interleukin-6, soluble Intracel-
lular Adhesion Molecule-1 (sICAM-1) and Insulin-like
Growth Factor-1 were assayed by commercial ELISA
(Biopool, R&D). Baseline plasma leptin was measured by
an ‘in house’ radioimmunoassay [19]. Baseline Factors
VII, VIII & IX, fibrinogen and activated protein C
(APC) ratio were assessed using commercial coagulation
assays (MDA Coagulometer, Biomerieux, Basingstoke,
UK). Baseline high sensitivity C-reactive protein (CRP)
[20] and lipoprotein (a) (Lp(a)) [21] were analyzed by
automated particle-enhanced immunoturbimetric assay
PROSPER participants 
Not on warfarin 
n=5699 
VTE cases 
Not on warfarin 
n=72
All VTE cases 
n=76
Non-cases 





Definite VTE cases 
Not on warfarin 
n=48
Probable VTE cases 





All VTE non-cases 
n=5728 
Controls, 2 per each 
case 
n=152 
Controls (2 per 





Nested case-control analysis   Cohort analysis 
Controls not on 
warfarin, for definite 
cases 
n=93
Figure 1 Flow diagram demonstrating identification of VTE cases, non-cases and controls in PROSPER.
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Age (years) 74.9 (3.1) 75.3 (3.4) 0.83 (0.54, 1.28) 0.39
Body mass index (kg/m2) 28.5 (5.2) 26.8 (4.2) 1.09 (1.02, 1.15) 0.0075
Total cholesterol (mmol/L) 5.5 (1.1) 5.7 (0.9) 0.80 (0.57, 1.10) 0.17
Triglyceride (mmol/L) 1.5 (0.9) 1.5 (0.7) 0.86 (0.56, 1.34) 0.51
LDL (mmol/L) 3.6 (0.9) 3.8 (0.8) 0.78 (0.54, 1.12) 0.18
HDL (mmol/L) 1.3 (0.4) 1.3 (0.3) 1.04 (0.89, 1.21) 0.65
Systolic blood pressure (mmHg) 147.7 (21.9) 154.7 (21.8) 0.74 (0.57, 0.97) 0.027
Diastolic blood pressure (mmHg) 83.2 (12.4) 83.8 (11.4) 0.96 (0.74, 1.23) 0.73
Men 22 (45.8) 2694 (47.9) 0.94 (0.53, 1.66) 0.83
Current smoker 12 (25.0) 1519 (27.0) 0.93 (0.48, 1.79) 0.82
History of vascular disease
History of hypertension 32 (66.7) 3493 (62.1) 1.22 (0.67, 2.22) 0.52
History of diabetes 5 (10.4) 603 (10.7) 1.00 (0.40, 2.53) 1.00
History of vascular disease 16 (33.3) 2446 (43.5) 0.66 (0.36, 1.20) 0.18
History of MI 7 (14.6) 722 (12.8) 1.19 (0.53, 2.65) 0.67
History of angina 13 (27.1) 1519 (27.0) 1.01 (0.54, 1.91) 0.97
History of CHD 15 (31.3) 1758 (31.2) 1.01 (0.55, 1.86) 0.97
History of claudication 2 (4.1) 371 (6.6) 0.63 (0.15, 2.58) 0.52
History of arterial surgery or amputation for vascular
disease
2 (4.1) 312 (5.5) 0.75 (0.18, 3.10) 0.69
History of peripheral arterial disease 3 (6.3) 603 (10.7) 0.57 (0.18, 1.82) 0.34
History of stroke/TIA 4 (8.3) 615 (10.9) 0.75 (0.27, 2.10) 0.59
Disability and cognition
IADL score 13.6 (1.1) 13.6 (1.0) 0.93 (0.72, 1.19) 0.55
Mini mental state exam (MMSE) score 27.6 (1.6) 28.0 (1.6) 0.84 (0.71, 0.99) 0.034
Barthel index score 19.7 (0.7) 19.8 (0.7) 0.93 (0.66, 1.30) 0.66
Years in education 15.0 (2.0) 15.1 (2.0) 0.98 (0.85, 1.13) 0.76
Country of origin
Scotland 21 (43.8) 2466 (43.8) 4.26 (1.00, 18.21) 0.034
Ireland 25 (52.1) 2104 (37.4) 6.16 (1.46, 26.00)
Netherlands 2 (4.2) 1057 (18.8) Referent
Drug treatment
Pravastatin treatment 28 (58.3) 2795 (49.7) 1.42 (0.80, 2.52) 0.23
Co-morbidities
Cancer during the study 11 (22.9) 415 (7.4) 4.58 (2.33, 9.01) <0.0001
Inflammation
IL-6* (pg/ml) 2.8 (2.1) 2.6 (1.9) 1.21 (0.80, 1.85) 0.37
sICAM-1* (ng/mL) 358 (1.41) 372 (1.39) 0.74 (0.31, 1.76) 0.50
CRP* (mg/L) 3.6 (3.1) 3.1 (3.1) 1.16 (0.90, 1.50) 0.25
Leptin* (ng/mL) 16.9 (2.4) 13.4 (2.4) 1.34 (0.97, 1.85) 0.077
Lipids
Lp(a)* (mg/dL) 11.2 (2.8) 13.6 (3.5) 0.89 (0.71, 1.11) 0.30
Apo A1 (g/L) 1.3 (0.2) 1.3 (0.2) 0.92 (0.29, 2.97) 0.89
Apo B (g/L) 1.1 (0.2) 1.1 (0.2) 0.45 (0.12, 1.66) 0.23
Biochemistry
Glucose* (mmol/L) 5.2 (1.2) 5.3 (1.2) 0.58 (0.13, 2.58) 0.47
Creatinine (umol/L) 104.2 (23.5) 101.1 (22.3) 1.01 (0.99, 1.02) 0.33
Urea*(mmol/L) 5.7 (1.4) 6.1 (1.3) 0.45 (0.16, 1.24) 0.12
ALT* (U/L) 22.3 (1.5) 21.3 (1.5) 1.32 (0.69, 2.54) 0.40
AST*(U/L) 24.3 (1.3) 23.5 (1.4) 1.38 (0.59, 3.21) 0.45
Freeman et al. BMC Geriatrics 2011, 11:8
http://www.biomedcentral.com/1471-2318/11/8
Page 4 of 8
and latex agglutination assay respectively. For blood
analyses listed in Table 1 data was already available in
the PROSPER database for all participants. For the coa-
gulation analytes and IGF-1, the analyses were carried
out specifically for the purposes of the current study
and were performed in cases and matched controls only
due to limited resource.
Statistical analysis
Data were analyzed using SAS vs9.1 (SAS Institute Inc,
Cary NC). Where necessary continuous variables were
transformed logarithmically to give a near-normal dis-
tribution of data for parametric analysis. Where data
were available from the entire cohort, analyses were
carried out using cases and non-cases (n = 5627) not
using warfarin at baseline, including 2834 patients allo-
cated to pravastatin and 2865 to placebo. The time to
VTE was quantified by univariate hazard ratios and
95% confidence intervals calculated with Cox’s propor-
tional hazard model for each variable of interest. In
the multivariate analyses, forward stepwise regression
was undertaken, where all variables significant at the
5% level on univariate analysis were allowed to enter
the model, to determine the subsets of variables that
were independently associated with VTE. Where data
were available only for the cases and controls (Factor
VIII, fibrinogen, PAI-1, IGF-1, Factor VII, Factor IX,
APC ratio), statistical analyses included calculation of
the conditional logistic regression univariate odds ratio
(which accounts for matching). For continuous vari-
ables, the odds ratio is that associated with 1 standard
deviation difference (in the control group) in the vari-
able of interest. A post hoc power calculation suggests
that we had 60-97% power to detect an odds ratio of
similar magnitude (0.4-0.6) to previously published
observational studies [4-9].
Results
Pravastatin use and VTE
There were 28 cases of definite VTE in 2834 non-war-
farinised patients in the pravastatin group and 20 cases
in 2865 allocated to placebo (Additional file 1 Table S1).
The unadjusted hazard ratio for VTE in the pravastatin
versus placebo group was 1.42 (95% confidence interval
0.80, 2.52; p = 0.23) (Table 1). The results were similar
after adjusting for cancer diagnosis in a multivariate
analysis [1.36 (0.77, 2.42) p = 0.29] and when analysing
only those participants without an incident cancer [1.51
(0.78, 2.90) p = 0.22]. An analysis was also carried out
in the group combining a definite and a probable diag-
nosis of VTE where the unadjusted hazard ratio for
VTE in the pravastatin versus placebo group was 1.20
(0.75, 1.90), p = 0.45.
Clinical and plasma risk markers in entire PROSPER cohort
Baseline data for definite VTE cases and non-cases in
the PROSPER cohort are shown in Table 1. Higher
body mass index was associated with an increase in risk
for VTE [1.09 (1.02, 1.15) p = 0.0075]. Systolic blood
pressure (increase of 20 mmHg) was associated with a
reduced risk of VTE [0.74 (0.57, 0.97) p = 0.027. Higher
MMSE score was associated with a reduced risk of VTE
[0.84 (0.71, 0.99) p = 0.034]. Subjects living in Scotland
were 4.26 (1.00, 18.21) and subjects in Ireland were 6.16
(1.46, 26.00) times more likely to have a VTE compared
to subjects living in the Netherlands (p = 0.034). In the
stepwise model only BMI [1.09 (1.03, 1.16) p = 0.0053],
systolic blood pressure (increase of 20 mmHg) [0.73
(0.56, 0.95) p = 0.021] and country [Scotland vs Nether-
lands 3.98 (0.93, 17.03) and Ireland vs Netherlands 5.62
(1.33, 23.76) p = 0.049] were independently predictive of
VTE. Analysis using a combined group of definite and
possible VTE gave similar results, apart from the asso-
ciation with systolic blood pressure which was not a sig-
nificant predictor of combined VTE in both univariate
and multivariate analysis.
Plasma risk markers in nested case control study
Baseline data in the nested case (n = 48) control (n =
93) study for Factors VIII, fibrinogen, PAI-1, IGF-1, Fac-
tor VII, Factor IX and APC ratio are shown in Table 2.
Plasma factor VIII levels were associated with an
increased risk of definite VTE [1.52 (1.01, 2.28) p =
0.044]. None of these risk markers was associated with
an increased risk of combined definite and probable
VTE.
Table 1 Variables at baseline in the whole cohort not on warfarin and risk of definite VTE (Continued)
Creatine Kinase* (U/L) 84.0 (1.6) 82.6 (1.6) 1.06 (0.60, 1.86) 0.84
Free T4* (nmol/L) 17.6 (1.2) 16.3 (1.2) 1.77 (0.61, 5.15) 0.30
TSH* (mU/L) 1.6 (2.0) 1.8 (2.4) 0.89 (0.66, 1.20) 0.45
Hematology
Hemoglobin (g/dL) 14.2 (1.2) 14.0 (1.2) 1.15 (0.92, 1.44) 0.22
Hematocrit (L/L) 0.4 (0.03) 0.4 (0.04) 1.22 (0.90, 1.65) 0.19
Mean and standard deviation (SD), *geometric mean (SD) calculated from the log transformed distribution or n (%) for categorical variables are shown. Hazard
ratios and confidence intervals are for increases of 1 unit, except for age (increase of 5 years), SBP (increase of 20 mmHg), DBP (increase of 10 mmHg),
hematocrit (increase of 0.04 L/L) and log free T4 (increase of 0.2 log unit).
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Risk factor profile in cancer-associated VTE and non
cancer-associated VTE
Cancer is a recognised risk factor for VTE. In the cur-
rent study cases were divided into cancer-associated
(n = 11) and non cancer-associated (n = 37) VTE. The
hazard ratio for cancer as a predictor of VTE was 4.58
(2.33, 9.01), P < 0.001 when comparing cases with non-
cases (Table 1). Including cancer as a variable in the
stepwise multivariate model had no impact on the asso-
ciations we observed. There were more new cases of
cancer in the pravastatin group than in the placebo
group [15] (Additional file 1 Table S1) and since the
etiology of VTE might differ between those with a
diagnosis of cancer and those without we explored the
possibility that baseline risk factor profile differed
between cases who had cancer and cases who did not
have cancer. We classified cancer-associated VTE as
those individuals who had a VTE subsequent to their
cancer diagnosis (n = 5) and those who had a VTE prior
to their cancer diagnosis (n = 6), total 22.9%. There
were no differences in risk factor profile between those
who had the VTE before and those who had a VTE
after their cancer diagnosis.
Discussion
This study showed with data from a randomized con-
trolled trial a lack of a protective effect of pravastatin on
VTE incidence in the elderly [1.42 (0.80, 2.52) p = 0.23].
The recently published data from the JUPITER study
[11] indicated that rosuvastatin significantly reduced the
occurrence of symptomatic VTE [0.57 (0.37, 0.86) p =
0.007] in middle-aged subjects with low LDL cholesterol
and raised C-reactive protein levels. The PROSPER
study had 48 VTE events (from 18,363 person-years of
follow-up in those not on warfarin), fewer than the 94
events seen in JUPITER (17,802 participants with med-
ian follow up of 1.9 years). However incidence rates
were similar: 0.26% for PROSPER and 0.28% for JUPI-
TER. In PROSPER new cancer diagnoses were more fre-
quent in the pravastatin treated group than in the
placebo treated group [15]. However the lack of effect of
pravastatin on VTE incidence was also observed when
only considering participants with no diagnosis of
cancer. Interestingly a very large, unselected population-
based cohort study (n = 129,288) looking at statin use
and a number of health outcomes [22] found a similar
lack of effect of statins on VTE incidence to that
observed in PROSPER.
The differing results in the PROSPER and JUPITER
studies may be explained by the different characteristics
of the populations. PROSPER was an elderly, high risk
population. JUPITER was carried out in a younger, initi-
ally healthy population although they did note a similar,
but not statistically significant, benefit in a high risk
subgroup of elderly participants ≥ 70 years of age. In
PROSPER, LDL cholesterol levels were approximately
1.0 mmol/L higher and CRP levels approximately
1.0 mg/L lower than those observed in the JUPITER
study. It is possible that more VTE events in JUPITER
had an underlying etiology involving pro-inflammatory
pathways [23] that may be susceptible to statin interven-
tion. Notably inflammation markers, and in particular
CRP, were not independently linked to VTE risk in
PROSPER. Since our study involved the use of pravasta-
tin we cannot rule out the possibility that the apparent
lack of efficacy in VTE prevention is confined to pravas-
tatin alone. However both pravastatin and rosuvastatin
which was used in JUPITER are water-soluble statins
and thus differences in tissue distribution are unlikely to
explain the difference between the effects of these drugs
on VTE events. Individual data meta-analyses of VTE
risk in randomized placebo controlled trials with statins
would be useful to address this issue and the low power
of single trials. Nevertheless, our results go against a
class effect of statins in VTE which is somewhat surpris-
ing since all statins lessen cardiovascular disease risk
including in the elderly.
BMI, lower systolic blood pressure and country of ori-
gin were the only significant independent predictors of
VTE in PROSPER. BMI was previously observed to be a
risk factor for VTE in the prospective Copenhagen City
Heart Study [24], Physicians’ Health Study [25] and
LITE study [26] where the subjects were predominately
aged <70 years. BMI appears to be more strongly
Table 2 Plasma risk markers in nested case control study where subjects were not on warfarin
Cases (n = 48) Controls (n = 93) Odds ratio (95% CI) P-value
Factor VIII (iu/dL) 158.4 (42.0) 144.6 (38.2) 1.52 (1.01, 2.28) 0.044
Fibrinogen (g/L) 3.60 (0.61) 3.73 (0.79) 0.81 (0.54, 1.24) 0.34
PAI-1 (ng/mL) 58.5 (35.9) 58.8 (30.9) 0.97 (0.68, 1.38) 0.86
IGF-1 (ng/mL) 74.0 (19.2) 76.0 (24.3) 0.92 (0.63, 1.34) 0.66
Factor VII (iu/dL) 135.0 (32.8) 137.9 (32.5) 0.85 (0.56, 1.29) 0.45
Factor IX (iu/dL) 138.6 (30.0) 140.4 (26.8) 0.94 (0.66, 1.33) 0.72
APC ratio 3.83 (1.19) 3.87 (1.12) 0.96 (0.66, 1.40) 0.85
Means (SD) are shown. Unadjusted odds ratios for continuous variables with approximately 1 SD change (SD in control group) are shown.
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associated with VTE than with either stroke or coronary
heart disease [25]. In our elderly population the magni-
tude of risk associated with BMI appears less than that
observed in younger populations. It is possible that the
association between BMI and VTE is attenuated by age.
Many mechanisms by which obesity may increase the
risk of VTE have been proposed, including promotion
of inflammation by adipokines, increased coagulation
activity, decreased fibrinolysis, increased oxidative stress,
metabolic disturbances and endothelial dysfunction [27].
We found that low systolic blood pressure was an inde-
pendent risk factor for incident VTE. This contrasts
with prospective studies of VTE in younger adults, in
whom a positive association has been observed with
high blood pressure [24]. However it is possible that
there is a change in the relationship of blood pressure
with risk of VTE with advancing age. In support of this
blood pressure levels in very elderly people have an
apparently paradoxical inverse relationship with risk of
other adverse clinical events including total mortality.
Low blood pressure in elderly people is likely to be asso-
ciated with more severe underlying covert disease
including coronary heart disease; often these underlying
diseases are unrecognized because there may be no clas-
sical symptoms [28]. It is likely that low blood pressure
in older people is a risk marker for VTE, rather than
directly causative. The lower incidence of definite VTE
in the Netherlands (0.19%) compared to Scotland
(0.84%) and Ireland (1.17%) is likely to reflect a healthier
cohort in this country; in the Netherlands there was
lower incidence of most recorded adverse outcomes,
including ischemic vascular events, compared to the
other 2 countries. Baseline BMI was not different
between randomised subjects from each country [16].
Our finding that coagulation Factor VIII was associated
with risk of definite DVT is consistent with reports
from several other cross-sectional studies, and from two
prospective studies (reviewed in [29]).
There were limitations to our study. It is a post hoc
analysis on a subgroup from the PROSPER study. The
subjects were from a selected population with either evi-
dence of pre-existing vascular disease or at least one
major risk factor for vascular disease. Thus our results
can only be applied to such high risk individuals. How-
ever this is the very subgroup of older people who are
likely to be considered for statin therapy. The number
of VTE is small and we may not be able to detect a
small effect of pravastatin treatment. The incidence of
definite VTE in the current study of 0.26% per annum is
less than that predicted for the very old (1% per annum
[1]) but equivalent to that observed in JUPITER (0.28%
per annum). This may have been due to a higher pro-
portion of relatively healthy and active individuals
volunteering to take part in a randomized controlled
trial, the use of cancer at baseline as an exclusion criter-
ion and insufficient recorded data to identify all cases.
The analysis presented here used definite VTE cases
only however analysis using a combination of definite
and probable VTE gave similar results. The PROSPER
database did not have information on transient or preci-
pitating risk factors, other than cancer, that may have
preceded a VTE, such as immobilization or previous
general surgery.
Conclusions
In conclusion we found that pravastatin does not pre-
vent VTE in elderly people at risk of vascular disease.
Blood markers of haemostasis and inflammation are not
strongly predictive of VTE in the elderly however BMI,
country and lower systolic blood pressure are indepen-
dently associated with VTE risk.
Additional material
Additional file 1: Table S1. Characteristics at baseline by treatment
group in PROSPER participants not on warfarin
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